179 results on '"Leleu, A."'
Search Results
2. HTA332 Evaluating Transcatheter Valve Replacement in Tricuspid Regurgitation: Complexities and Limitations of Existing Models
3. EE241 Budget Impact of Making Emicizumab Available at the Community Pharmacy in Addition to the Hospital Pharmacy
4. EPH165 Assessing Public Health Models in France: A Systematic Review
5. PT17 Modelling Treatment Duration in Psoriasis: Examining Extrapolation Approaches and Implications
6. EPH16 Exploring the Effects of the COVID-19 Pandemic on Pneumococcal Disease in France: A Comprehensive Analysis of Public Health Impact and Economic Burden
7. EPH47 Modeling the Impact of the Vaccine Candidate TAK-003 on the Incidence of Dengue in French Overseas Territories
8. EE577 Early Initiation of Guselkumab Increases Duration of Complete Remission (Psoriasis Area and Severity Index 100) in Patients With Moderate-to-Severe Psoriasis
9. P25 Association between Adherence to Lenalidomide and Patient-Reported Outcomes in Patients with Multiple Myeloma: A Systematic Literature Search
10. EPH181 Are Social Networks Harming Our Teens? Assessing the Plausibility of a Link between Social Network Use and Depression Using a Microsimulation Model
11. PCR156 Improving Precision of Societal Budget Impact Analysis of Emicizumab Delivery Options in France: Insights From the Hemivalue Study Using Real-World Data From the PASO DOBLE DEMI Study.
12. EPH122 Healthcare Consumptions in Patient with Early Ageing Disease: Case-Control Study From a National Claims Database
13. EE630 A Cost-Effectiveness Analysis (CEA) of Adjuvant Nivolumab for Patients With Resected Esophageal Cancer (EC) or Gastroesophageal Junction Cancer (GEJC) in France
14. CO103 Prognostic Models for Short-Term Annual Risk of Severe Acute Complications and Mortality in Patients Living With Type 2 Diabetes Using a National Medical Claim Database
15. EPH167 Proportions of Avoidable GP Visits in France: Findings From a National Claims Database
16. EPH47 Early Hospital Management of Ageing Disease: Retrospective Study From a National Claims Database
17. EPH68 Epidemiological Impact of Generalized SARS-COV-2 Vaccination of Children Aged 5 to 11
18. EPH121 Future Trends of the COVID-19 Pandemics: What Should We Expect?
19. MSR80 Impact of Donor Ferritin Testing on Iron Deficiency Prevention and Blood Availability in France: A Cohort Simulation Study
20. EPH243 First Real-World Evidence Onbudesonide/Glycopyrronium/Formoterol Fumarate(BGF) Use for COPD Patients in France (ENARXI Study)
21. EE137 Cost-Effectiveness Analysis of Neoadjuvant Nivolumab Plus Platinum-Based Chemotherapy (PDC) in Resectable Non-Small Cell Lung Cancer (NSCLC) in France: A Situation of Dominance
22. EE113 Follitropin Delta Is Cost-Effective Versus Follitropins Alfa and Beta in Controlled Ovarian Stimulation for Assisted Reproductive Technologies (ART) in France
23. MSR80 Impact of Donor Ferritin Testing on Iron Deficiency Prevention and Blood Availability in France: A Cohort Simulation Study
24. EPH121 Future Trends of the COVID-19 Pandemics: What Should We Expect?
25. EPH167 Proportions of Avoidable GP Visits in France: Findings From a National Claims Database
26. EE630 A Cost-Effectiveness Analysis (CEA) of Adjuvant Nivolumab for Patients With Resected Esophageal Cancer (EC) or Gastroesophageal Junction Cancer (GEJC) in France
27. EPH47 Early Hospital Management of Ageing Disease: Retrospective Study From a National Claims Database
28. EPH122 Healthcare Consumptions in Patient with Early Ageing Disease: Case-Control Study From a National Claims Database
29. CO103 Prognostic Models for Short-Term Annual Risk of Severe Acute Complications and Mortality in Patients Living With Type 2 Diabetes Using a National Medical Claim Database
30. EPH68 Epidemiological Impact of Generalized SARS-COV-2 Vaccination of Children Aged 5 to 11
31. POSC34 Comparative Efficacy and Safety of Isatuximab Plus Pomalidomide and Dexamethasone Versus Daratumumab Plus Pomalidomide and Dexamethasone in Patients with Multiple Myeloma Using a Matching-Adjusted Indirect Comparison
32. POSB404 Therapeutic Management of Multiple Myeloma and Healthcare Resource Assessment By Matching the Emmy Cohort to the Data of the National Health Data System (SNDS) in France
33. POSA300 Combining Clinical Trial and Real-World Evidence Data in the Assessment of Public Health Impact in HTA Evaluations
34. POSB404 Therapeutic Management of Multiple Myeloma and Healthcare Resource Assessment By Matching the Emmy Cohort to the Data of the National Health Data System (SNDS) in France
35. POSC34 Comparative Efficacy and Safety of Isatuximab Plus Pomalidomide and Dexamethasone Versus Daratumumab Plus Pomalidomide and Dexamethasone in Patients with Multiple Myeloma Using a Matching-Adjusted Indirect Comparison
36. PCN161 Disease Burden of Multiple Myeloma (MM) in France: A Descriptive Study Based on a French Medico-Administrative Database
37. PIN151 Adaptation and Calibration of a Markov MODEL Framework in Hepatitis D
38. PCN133 Disease Burden of Hodgkin's Lymphoma in France: A Descriptive Study Based on a French Medico-Administrative Database
39. PBI8 Use of Biosimilars in Haematology in France: A Descriptive Study Based on a French Medico-Administrative Database
40. PCN77 Disease Burden of Chronic Lymphoid Leukemia (CLL) in France: A Descriptive Study Based on a French Medico-Administrative Database
41. PCN133 Disease Burden of Hodgkin's Lymphoma in France: A Descriptive Study Based on a French Medico-Administrative Database
42. PIN151 Adaptation and Calibration of a Markov MODEL Framework in Hepatitis D
43. PCN161 Disease Burden of Multiple Myeloma (MM) in France: A Descriptive Study Based on a French Medico-Administrative Database
44. PBI8 Use of Biosimilars in Haematology in France: A Descriptive Study Based on a French Medico-Administrative Database
45. PCN77 Disease Burden of Chronic Lymphoid Leukemia (CLL) in France: A Descriptive Study Based on a French Medico-Administrative Database
46. PCN318 CLINICAL AND TREATMENT CHARACTERISTICS OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN EUROPE
47. PIN96 EPIDEMIOLOGICAL AND ECONOMIC IMPACTS OF POTENTIAL HCV SCREENING STRATEGIES FOR THE NEXT 5 YEARS IN FRANCE
48. PIN23 TREATING PATIENTS WITH DAAS ALLOWED TO SAVE 1 BILLION EUROS IN FRANCE - A BUDGET IMPACT MODEL FROM 2014 TO 2018
49. PIN96 EPIDEMIOLOGICAL AND ECONOMIC IMPACTS OF POTENTIAL HCV SCREENING STRATEGIES FOR THE NEXT 5 YEARS IN FRANCE
50. PCN255 ESTIMATION OF THE POTENTIAL IMPACT OF THE FRENCH CRC SCREENING PROGRAM BASED ON REAL-WORLD PARTICIPATION RATES
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.